PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from ...
Inovio Pharmaceuticals, Inc. INO announced that it has completed enrollment in a phase II study, evaluating its investigational HPV immunotherapy — VGX-3100 — for the treatment of vulvar dysplasia ...
PLYMOUTH MEETING, Pennsylvania, July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients ...
Nov. 5 -- WEDNESDAY, Nov. 4 (HealthDay News) -- A vaccine that targets human papillomavirus (HPV) is able to stop precancerous lesions in the vulva from progressing into full-blown malignancies, Dutch ...
Prakash Bhuyan, MD, PhD, vice president of clinical development at Inovio, discusses the company's vaccine trial for coronavirus disease 2019 (COVID-19) as well as its DNA medicine platform for rare ...
* INOVIO PHARMACEUTICALS - REPORTING INTERIM DATA ON 10 SUBJECTS WHO COMPLETED PRIMARY ENDPOINT EVALUATION AT SIX MONTHS FOLLOWING TREATMENT WITH VGX-3100 * INOVIO PHARMACEUTICALS - VGX-3100 DNA ...
The biotech's coronavirus vaccine candidate gets the spotlight, but you might want to shine some light on this program, too. It makes sense why INO-4800 is the primary focus of investors. If the ...
Picking up an over-the-counter soothing vulva cream at your local drugstore might seem like an easier solution to treat itching or dryness than scheduling time with your doctor, but if you're ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback